Physician profile
Jerry A Berg
NPI 1467900951
$34,306.31
in general payments reported to CMS, 2019-2025
33 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,709 · 2022: $2,267 · 2023: $8,558 · 2024: $6,726 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $8,641 · Travel and Lodging: $3,484 · Consulting Fee: $2,600 · Honoraria: $2,600 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,895.00 |
| Food and Beverage | $8,641.32 |
| Travel and Lodging | $3,484.17 |
| Consulting Fee | $2,600.00 |
| Honoraria | $2,600.00 |
| Education | $109.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $15,902.75 | 2024-2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $6,331.83 | 2021-2023 | |
| Abbvie INC. | $2,935.48 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,394.05 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Ardelyx, INC. | $1,152.35 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $1,045.57 | 2021-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $620.55 | 2021-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $486.53 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $451.37 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $382.51 | 2022-2025 | Dupixent |
| Vivus LLC | $380.07 | 2021-2025 | Qsymia, Pancreaze |
| Merck Sharp & Dohme LLC | $349.51 | 2021-2023 | Dificid |
| Pfizer INC. | $273.35 | 2021-2025 | |
| Redhill Biopharma INC. | $224.19 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $209.02 | 2021-2024 | Linzess |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $166.05 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $129.59 | 2021-2023 | Injectafer |
| Madrigal Pharmaceuticals | $125.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $123.13 | 2021-2024 | Rebyota, Clenpiq |
| Gilead Sciences, INC. | $116.56 | 2021-2023 | |
| Braintree Laboratories, INC. | $104.84 | 2022-2025 | Suflave, Sutab |
| Digestive Care, INC. | $89.27 | 2023-2025 | Pertzye |
| Ipsen Biopharmaceuticals, INC | $68.43 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.95 | 2023-2024 | Cyltezo |
| Biocon Biologics INC | $40.50 | 2025 | Yesintek |
| Organon LLC | $32.75 | 2022 | |
| Intercept Pharmaceuticals, INC. | $28.94 | 2022-2023 | Ocaliva |
| Celgene Corporation | $25.00 | 2022-2023 | Zeposia |
| Fresenius Kabi USA, LLC | $16.14 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $15.96 | 2022 | |
| Celltrion USA INC. | $13.88 | 2025 | Vegzelma |
| Ultragenyx Pharmaceutical INC. | $12.57 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.